Conversant Bio merges with Folio Biosciences

Conversant Bio, an associate company located on the HudsonAlpha campus, has merged with Folio Biosciences to create the life science industry’s premier provider of research services and biospecimen solutions: Folio Conversant.

Folio Conversant will offer an extensive array of quality biospecimens, particularly FFPE tissue and blood, supported by comprehensive laboratory and analytic services.

Conversant Bio was one of the first companies to join the HudsonAlpha campus as a two-person startup and has grown to become the largest U.S. custom blood procurement company for oncology and rheumatology research. Conversant Bio’s success has been built on a large prospective collections network of more than 70 IRB reviewed clinical sites. Through dedication to customer service, the company supported more than 1,500 research projects in 2017 alone.

“By combining Folio and Conversant’s capabilities, we will be uniquely positioned to address the highly specific needs of our customers,” said Marshall Schreeder, Conversant Bio co-founder and CEO. “We will be especially adept at supporting earlier-stage research that requires particular or difficult-to-obtain specimens and insights.”

Established by a Nobel-prize winning scientist, Folio is the largest U.S. biobank with more than 8 million specimens, primarily FFPE tissue. The Columbus, Ohio-based company offers custom-procurement, pathology and histology services, including an in-house CLIA certified lab for sectioning and TMA manufacturing of human tissues. Over the years, Folio has earned a reputation as a high-quality science provider of biospecimens and analytical services.

“Folio was founded on the principle of providing customers with the highest quality biospecimens and clinical insights to advance their work toward finding new cures and treatments,” said Adel Mikhail, PhD, co-founder and CEO. “I’m extremely pleased to be joining forces with another leader who shares this commitment.”

To learn more, visit